Younger age (≤40), late‑line therapy, and prior platinum were linked to shorter PFS.
Toxicities were manageable, with hematologic AEs most common.
This study adds valuable Asian real‑world evidence to guide PARPi use.
#BreastCancer #PARPi #RWE #PrecisionOncology